Spear Bio is attending the 5th ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, where leaders across biotech, pharma, academia, clinical development, regulatory science, and patient advocacy will come together to accelerate the next generation of ALS and FTD therapeutics. 

As ALS and FTD programs increasingly rely on more predictive translational strategies, patient stratification, longitudinal monitoring, and blood-based biomarker insights, Spear Bio is helping researchers detect low-abundance protein biomarkers with exceptional sensitivity from ultra-small sample volumes.

Featured Presentation

SPEAR Immunoassays for Neurodegenerative Biomarker Detection
Wednesday, June 3, 2026 | 9:00 am ET

• A novel immunoassay platform enabling ultra-sensitive detection of low-abundance neurological biomarkers in blood
• Advancing translational and clinical research through high sensitivity, specificity, and precision across challenging neurodegenerative biomarkers
• Expanding beyond established biomarkers with custom assay development to support biomarker-driven therapeutic development